Ritholtz CEO Josh Brown Names Incyte and Biogen as Top Picks Amid AI Sector Shift

NEW YORK, Aug. 30 (AP) — Josh Brown, chief executive of Ritholtz Wealth Management, identified Incyte Corporation and Biogen Inc. as leading investment opportunities on Friday, signaling a strategic pivot away from the artificial intelligence and data-center spending themes that have dominated Wall Street for the past two years.

Brown highlighted the biotechnology firms during a market commentary session in the United States, emphasizing their robust earnings momentum and expanding drug pipelines as key drivers for future growth. The recommendations come as investors increasingly seek exposure to sectors grounded in tangible fundamentals rather than speculative technology trends.

Incyte Corporation (NASDAQ: INCY) was singled out for its consistent financial performance and a pipeline of therapeutic candidates showing promise across oncology and inflammation markets. Brown noted that the company's ability to generate steady revenue streams positions it favorably against broader market volatility. The firm has recently advanced several late-stage trials, reinforcing its capacity to deliver near-term value to shareholders.

Biogen Inc. (NASDAQ: BIIB) was similarly endorsed for its strong operational metrics and strategic focus on neurodegenerative diseases. Despite facing headwinds in previous quarters related to patent cliffs and competitive pressures, Biogen has demonstrated resilience through cost-cutting measures and the successful commercialization of new treatments. Brown pointed to the company's diversified portfolio as a stabilizing factor in an unpredictable economic environment.

The selection of these two pharmaceutical giants reflects a broader sentiment among some asset managers who are recalibrating portfolios to reduce reliance on mega-cap technology stocks. With valuations in the AI sector reaching historic highs, Brown argued that traditional healthcare equities offer a more balanced risk-reward profile for long-term investors.

"We are looking for companies with proven earnings power and clear paths to profitability," Brown stated, underscoring the shift toward fundamental analysis over thematic speculation. This approach marks a departure from the heavy rotation into semiconductor and cloud-computing stocks that defined the market's trajectory in 2024 and 2025.

Market analysts remain divided on whether this sector rotation represents a temporary adjustment or a sustained trend. While some investors are eager to capitalize on undervalued healthcare assets, others caution that the biotech sector remains sensitive to regulatory changes and clinical trial outcomes. The success of Incyte's and Biogen's upcoming product launches will be critical in validating Brown's thesis.

As the trading day concluded, shares of both companies saw modest gains, though analysts noted that broader market conditions could influence their trajectory. Investors are now watching closely to see if other major fund managers follow suit in reallocating capital toward non-technology sectors. The extent to which this strategy gains traction remains an open question as the third quarter draws to a close.